The Pharma Data

DECEMBER 10, 2020

The goal of targeting both S and N was to both activate virus-specific T cells and generate anti-SARS-CoV-2-neutralizing antibodies. The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. This can significantly limit the effectiveness of first-generation platforms.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

APRIL 25, 2024

Grand View Research states that the market for cell lines is currently bolstered by the fact that the majority of biopharma companies use cell lines to synthesise recombinant monoclonal antibodies and proteins. It is a crucial for the development of biopharmaceuticals since they use a living host to produce the therapeutic in question.

Development 59

Development Protein In-Vivo Life Science 59

Drug Discovery World

APRIL 15, 2024

The company has a biologics pipeline with a focus on differentiated antibodies targeting a range of indications. Reece Armstrong speaks to Sean McClain , Founder & CEO of Absci about the rise of generative AI in life sciences.

Antibody 59

Antibody Drugs In-Vivo Life Science 59

Drug Discovery World

JULY 18, 2023

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. Years of development and fast-paced research have continued to unlock its potential, expanding how CRISPR can be used to treat, detect, and prevent common diseases such as cancer and Covid-19.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

NOVEMBER 15, 2022

Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery. . It has made its way into almost every aspect of drug discovery, whether it’s exploring basic biology, modelling diseases, identifying and validating targets, or performing drug screens. .

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

SEPTEMBER 6, 2022

This area of medicine, which turns our own bodies into agents of combat to fight disease, has quickly become one of the most promising fields in treating deadly diseases such as cancer, central nervous system disorders and even musculoskeletal conditions. . Last year saw the sector surge, with levels of investment hitting an all-time high at $22.7

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

pharmaphorum

JULY 13, 2022

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment. dosing of *first patient* with VERVE-101, an in vivo CRISPR base editing medicine. Today: we are announcing.

Gene Editing 98

Gene Editing Trials Drugs Gene 98

Pharma Marketing Network

JANUARY 20, 2021

Perhaps this omission is because the systemically administered vaccines are unable to stimulate robust immune responses in the mucosae, despite generating systemic neutralizing antibody (and possibly T cell) responses.

Vaccination 52

Vaccination Vaccine In-Vivo Genetics 52

The Pharma Data

OCTOBER 14, 2020

VBL Therapeutics – The European Patent Office granted a patent to Israel-based VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat inflammatory conditions. All jobs have been maintained and the workforce has grown from about 220 to 350. AOP anticipates new opportunities in Austria as a hub for research and business.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52